Relenza Growth Will Rely On Prophylaxis Use; Flovent Flies In U.S., Up 55%
Executive Summary
A Relenza prophylaxis indication is key to the future growth of the inhaled neuraminidase inhibitor, Glaxo Wellcome Chairman Richard Sykes said July 27 at a half-year results meeting in London.
You may also be interested in...
Roche Xenical Patient Compliance Could Increase With New DTC Campaign
Roche will attempt to increase patient compliance for its obesity drug Xenical through a multi-faceted direct-to-consumer campaign.
Roche Xenical Patient Compliance Could Increase With New DTC Campaign
Roche will attempt to increase patient compliance for its obesity drug Xenical through a multi-faceted direct-to-consumer campaign.
Glaxo's Lotronex Risk-Management Program Emphasizes Appropriate Use
Glaxo Wellcome is proposing an "appropriate use" campaign as the focus of its risk-management plan for Lotronex, the company told FDA's Gastrointestinal Drugs Advisory Committee June 27.